https://www.selleckchem.com/pr....oducts/eidd-2801.htm
This advancement in analytical technology has led to the development of numerous assays to detect analytes at low concentrations (pmol/L) in DBS specimens that can be used to monitor IMD patients. In this review, we discuss the pre-analytical, analytical and post-analytical variables that may affect the final test result obtained using DBS specimens used for monitoring of patients with an IMD.Every newborn bloodspot screening (NBS) result for cystic fibrosis (CF) consists of two parts a screening part in the laboratory and a clinical
Like
Comment
Share
